PRAP1 Inhibition for Hyperlipidemia With Fewer Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperlipidemia are inadequate due to low efficacy, intolerance, and significant side effects, necessitating a safer and more efficient method for managing elevated lipid levels in the blood.
Innovation Solution
Administering a PRAP1 inhibitor, such as a modified PRAP1 polypeptide or nucleic acid targeting PRAP1, to modulate lipid metabolism by reducing PRAP1 activity, which is involved in lipid absorption and apoB lipoprotein assembly and secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lipid-lowering medications (statins, bile-acid-binding resins, niacin, cholesterol absorption inhibitors, fibrates) are used to treat hyperlipidemia, then lipid levels may be reduced to some extent, but the treatment suffers from low efficacy, intolerance, and significant side effects including acute coronary syndrome, myopathy, rashes, gastrointestinal upset, skin vasodilation, flushing, bloating and diarrhea
Solution Approach 1:
The patent applies parameter changes by modifying the PRAP1 polypeptide structure through specific amino acid substitutions (E94V in human PRAP1, E88V in mouse PRAP1) to create a dominant-negative mutant that selectively inhibits PRAP1 function. This structural modification changes the protein's functional parameters to achieve potent lipid-lowering effects without the side effects of conventional medications.
Solution Approach 2:
The patent extracts and targets the specific PRAP1 protein function as the therapeutic intervention point. By using antisense oligonucleotides or small interfering RNA to specifically reduce PRAP1 expression, or by administering the modified PRAP1 polypeptide to inhibit endogenous PRAP1, the treatment selectively targets the harmful lipid metabolism pathway without affecting other physiological systems, thereby avoiding the broad side effects of conventional lipid-lowering drugs.
2Reliability
If PRAP1 activity is inhibited to lower plasma lipids, then triglyceride and phospholipid levels decrease and body weight and fat mass are reduced, but the treatment mechanism requires high specificity to avoid affecting other metabolic pathways
Solution Approach 1:
The patent uses antisense oligonucleotides or small interfering RNA as intermediaries to specifically reduce PRAP1 expression at the mRNA level. These nucleic acid molecules bind to PRAP1 mRNA through complementary base pairing, preventing translation and selectively reducing PRAP1 protein levels without affecting other proteins or metabolic pathways, thus achieving high specificity in lipid metabolism modulation.
Solution Approach 2:
The modified PRAP1 polypeptide exhibits local quality changes through site-specific amino acid mutations (E94V/E85V substitutions) that create a dominant-negative effect. These localized structural changes confer specific inhibitory activity against endogenous PRAP1 while maintaining the protein's ability to interact with specific binding partners, ensuring targeted modulation of lipid metabolism without broad systemic effects.
Data Source
AI summary
The present invention is directed to genetically-modified non-human animal models with specific mutations in exon 3 of proline-rich acidic protein 1 (PRAP1) gene. Also disclosed herein are methods of treating hyperlipidemia or a hyperlipidemia-related disease by using a PRAP1 inhibitor or a modified PRAP1 polypeptide, as well as pharmaceutical compositions comprising the modified PRAP1 polypeptide.